Our advanced AI-powered data analytics platform allows for seamless comparison of preclinical candidates with previously published assets within the same preclinical models. By analyzing these data sets, the technology enables Pharmaceutical companies and investors to correlate preclinical results with clinical trial outcomes, providing crucial insights that enhance decision-making process.

2 options to subscribe to those databases:

Here is the Free DEMO version of this database. For more info, please consult our FAQs.

Pre-clinical and Clinical results Databases :

Navigating the complex journey from preclinical drug candidates to market-ready therapeutics is fraught with challenges. With only about 1 percent of preclinical candidates successfully reaching the market, this process typically spans 12 years and demands an investment of approximately $2 billion. However, the advent of advanced AI-powered data analytics platforms offers transformative opportunities for pharmaceutical companies and investors to streamline drug development, save costs, and reduce time to market. This technological advancement has significant implications for scientific due diligence, an essential component of the drug development process.

Scientific due diligence is the meticulous evaluation of preclinical and clinical data to assess the viability and potential of a drug candidate. This process is critical for making informed decisions about which candidates to advance, invest in, or discontinue. Traditionally, scientific due diligence has been time-consuming and resource-intensive, involving the painstaking review of vast amounts of data. However, our advanced AI-powered data analytics platform revolutionizes this process by providing rapid, accurate, and comprehensive analyses of preclinical and clinical data.

Scientific Due Diligence

Our AI platform leverages sophisticated algorithms and extensive datasets to enable seamless comparisons of preclinical candidates with previously published assets within the same preclinical models. This capability is pivotal in providing pharmaceutical companies and investors with critical insights that enhance their decision-making processes. By integrating data from a comprehensive repository known as the Preclinical Reports Database, our AI platform identifies patterns and correlations that are not immediately apparent through traditional methods. This not only accelerates the evaluation process but also significantly enhances the accuracy of predicting clinical trial outcomes.

One of the primary advantages of utilizing our AI platform for scientific due diligence is substantial cost savings. The traditional route of drug development involves numerous trials and errors, with significant resources allocated to candidates that ultimately fail to progress. By employing our AI platform, pharmaceutical companies can make more informed decisions early in the development process, potentially reducing the number of failed candidates. This efficiency translates directly into cost savings, potentially reducing the $2 billion investment typically required.

Moreover, the AI platform aids in optimizing resource allocation. By providing detailed comparisons and insights, it helps identify the most promising candidates, enabling companies to focus their resources on those with the highest potential for success. This targeted approach not only conserves financial resources but also accelerates the development timeline. The traditional 12-year journey to market can be significantly shortened, as companies can fast-track candidates with a higher likelihood of success based on robust, data-driven insights.

Investors also stand to gain immensely from this technology. The ability to accurately predict the potential success of preclinical candidates can lead to more strategic investment decisions. By utilizing the AI platform and accessing the Preclinical Reports Database, investors can better assess the viability of their investments, reducing the risk of financial loss associated with unsuccessful drug candidates. This enhanced due diligence process ensures that investment portfolios are optimized for maximum return, aligning with the ultimate goal of advancing successful therapeutics to market more efficiently.

In conclusion, our advanced AI-powered data analytics platform offers a transformative solution for scientific due diligence in the pharmaceutical industry. By facilitating seamless comparisons, providing critical insights, and enabling more informed decision-making, this technology significantly reduces both the financial and temporal burdens of drug development. Pharmaceutical companies and investors alike can benefit from reduced costs, optimized resource allocation, and accelerated timelines, ultimately bringing effective therapeutics to market more swiftly and efficiently. The future of drug development is here, and it is powered by AI, revolutionizing the landscape of scientific due diligence.

Scientific Due Diligence

If you want to know more about this innovative tool and see a DEMO, please Contact us !

You want to add your results to this database ? If your results are already published in a peer-reviewed scientific paper, please Contact us !

Healthcare Venture Building : You have an IP on your molecule / New Drug / mAbs and you want to create a spin-off ? Startup structure, Team, Business strategy, Private Funding, Public Grants, Market Study, Patents, Regulatory, etc. We’ve got your back ! Contact us !